N/A N=242 The IPED (Investigation of Palpitations in the ED) Study
Presyncope · Arrhythmias, Cardiac · Tachycardia, Supraventricular
Primary: Number of Participants With Symptomatic Rhythm Detection up to 90 Days — 69; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=498 Diagnostic Accuracy of WEARable TECHnology Single-lead ECG in Detecting Cardiac Arrhythmias
Cardiac Arrhythmia · Atrial Fibrillation
Primary: Compare the Diagnostic Performance of Physician Rhythm Interpretation of 1-lead ECG Generated by SkyLabs CART-I Ring and Apple Watch Versus 12-lead ECG (Gold-standard)…
N/A N=39 Ambulatory Post-Syncope Arrhythmia Protection Feasibility Study
Syncope
Primary: Device Unable to Monitor Due to ECG Noise — 1.5 percentage of time worn
N/A N=86 Diagnostic Yield of an Ambulatory Patch Monitor in Unexplained Emergency Department Syncope: A Pilot Study (PATCH-ED)
Syncope
Primary: Number of Ambulatory Patch Monitor Participants Having Significant Symptomatic Arrhythmia — 9 Participants
N/A N=262 iPhone Helping Evaluate Atrial Fibrillation Rhythm Through Technology
Atrial Fibrillation · Atrial Flutter
Primary: Rate of Recurrence of Atrial Arrhythmias — 0.132; 0.091 episodes per person-month of follow-up — p=0.05
Phase 2 N=59 Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias
Premature Atrial Contraction
Primary: Change in Premature Atrial Contractions (PACs) — -0.6; -5.6 Episodes/hour
N/A N=100 A Study of Prolonged Electrocardiographic Monitoring in Patients With Heart Failure in Sinus Rhythm or Atrial Fibrillation
Heart Failure · Atrial Fibrillation
Primary: Number of Participants With an Identified Dysrhythmia on Baseline ECG Recording — 25; 35 Participants
N/A N=83 Effectiveness of Ripple Mapping in Atrial Tachycardia Ablation
Atrial Tachycardia
Primary: A Composite of the Total Number of Participants With Either Tachycardia Change or Tachycardia Termination With First Ablation Set. — 38; 29 Participants
Phase 3 N=26 Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: Change in Heart Rate — 17.0; 13.1 beats per minute
Phase 4 N=24 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit
Atrial Fibrillation
Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants
N/A N=151 Systemic Lupus Erythematous and Heart Conduction Disorders
Lupus Erythematosus, Systemic · Atrioventricular Block · Sudden Death
Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec
N/A N=17 Evaluation of the Use of Apple Watch Features for Identification of Cardiac Arrhythmias
Atrial Fibrillation · Arrhythmias, Cardiac · Atrial Flutter
Primary: Atrial Fibrillation or Atrial Flutter (AF) of at Least 30 Seconds Duration — 0.11 Proportion of participants
Phase 4 N=67 Heart Rate Regularization in Patients With Permanent Atrial Fibrillation Post Marketing Study
Permanent Atrial Fibrillation
Primary: Patients Mode Preference (VRS ON, VRS OFF, NO PREFERENCE) — 32; 32; 15; 15 participants — p=<0.0001
N/A N=8 Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients
Arrhythmias, Cardiac
Primary: Number of Participants With a Significant Arrhythmia Detected — 0 participants
N/A N=33 Validation of an iPhone-based Event Recorder for Arrhythmia Detection
Arrhythmia, Palpitations, Lightheadedness
Primary: Validation of an iPhone-based Event Recorder for Arrhythmia Detection — 14; 12; 8; 8 participants
Phase 4 N=59 Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Atrial Fibrillation
Primary: Number of Days on Anticoagulation — 24.9 days
N/A N=72 Efficacy of Personalized Exercise Program and Trimetazidine in Rehabilitation of Patients After RFA of AF
Atrial Fibrillation Paroxysmal
Primary: Atrial Fibrillation Recurrence — 2; 3; 7 Participants
N/A N=19 Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A
End Stage Renal Disease
Primary: Adherence With Proposed Interventions — 88; 90; 83; 80 Percentage of sessions
N/A N=13 Effect of Chronic Changes in Heart Rate on Congestive Heart Failure
Heart Failure, Congestive
Primary: Ejection Fraction — 33; 30; 25 % of blood ejected with each beat
N/A N=80 Supraventricular Tachycardia Collection Study
Supraventricular Arrhythmias
Primary: Number of Electrocardiograms (ECGs) Collected — 77; 67; 53 ECG
N/A N=256 Video-based Detection of Atrial Fibrillation
Atrial Fibrillation
Primary: Area Under the Receiver Operating Characteristic Curve (AUC) for the Detection of Atrial Fibrillation — 0.74 probability
Phase 2 N=237 PT003 MDI Cardiovascular Safety Study
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in 24-Hour Mean Heart Rate Post-dose — -0.19; -1.84; 0.40; -0.09 bpm
N/A N=400 Reducing Episodes by Septal Pacing Efficacy Confirmation Trial (RESPECT)
Atrial Fibrillation · Tachycardia, Supraventricular · Arrhythmia
Primary: Rate of Symptomatic Atrial Tachycardia/Atrial Fibrillation Episodes Per Subject Per Month — 2.0; 1.8 Episodes per subject per month — p=0.629
Phase 2 N=69 ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2
Atrial Fibrillation
Primary: The Maximum Reduction in Ventricular Rate, Measured on Holter Monitoring, Within 60 Minutes From Drug Administration. — 135.5; 130.3; 130.7; 95.2 bpm — p=<0.0001
Phase 2 N=22 Pilot Randomized Trial With Flecainide in ARVC Patients
Arrhythmogenic Right Ventricular Cardiomyopathy
Primary: Number of Ventricular Ectopic Beats (VEBs) Per Day — 2685; 677 number of VEBs per day — p=<0.0001
N/A N=573 Atrial Fibrillation Algorithms Clinical Validation Study
Atrial Fibrillation
Primary: SENSITIVITY OF IRREGULAR RHYTHM NOTIFICATION FEATURE [IRNF] — NA; NA; NA; 88.6 percentage of participants
N/A N=546 ECG App Algorithms Clinical Validation Study
Atrial Fibrillation
Primary: Percentage of Trials With Correct Classification of Normal Sinus Rhythm on Simultaneous 12-lead ECG as "Sinus Rhythm" or "High Heart Rate" on a Readable and Classifiable…
Phase 4 N=54 Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter
Heart Rate and Rhythm Disorders
Primary: Percent of Patients Reaching Target HR<100bpm Within 30 Minutes — 46.4; 95.8 percentage of participants — p=.0001
Phase 1 N=22 Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects
Drug-induced Surface ECG Changes
Primary: Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc — 6.5; 2.3; 32.1; 5.1 ms — p=<0.05
N/A N=24 Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure
Atrial Fibrillation · Heart Failure
Primary: Correlation of Heart Failure Risk Score (HFRS) With Heart Failure Events — 5; 2; 2; 7 participants